Randomized Trial of Lenalidomide, Bortezomib, Dexamethasone vs High-Dose Treatment With SCT in MM Patients up to Age 65 (DFCI 10-106)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01208662
Recruitment Status : Active, not recruiting
First Posted : September 24, 2010
Last Update Posted : June 14, 2018
Celgene Corporation
Millennium Pharmaceuticals, Inc.
Massachusetts General Hospital
Cape Cod Healthcare
Beth Israel Deaconess Medical Center
Emory University
University of Michigan
Fox Chase Cancer Center
Memorial Sloan Kettering Cancer Center
Fred Hutchinson Cancer Research Center
Barbara Ann Karmanos Cancer Institute
Duke University
University of California, San Francisco
University of Chicago
M.D. Anderson Cancer Center
UNC Lineberger Comprehensive Cancer Center
Roswell Park Cancer Institute
Stanford University
University of Mississippi Medical Center
Icahn School of Medicine at Mount Sinai
Wake Forest University Health Sciences
University of Arizona
OHSU Knight Cancer Institute
Eastern Maine Medical Center
University of California, San Diego
University of Alabama at Birmingham
University of Pittsburgh
Ochsner Health System
University of Texas Southwestern Medical Center
State University of New York - Downstate Medical Center
Newton-Wellesley Hospital
Baylor College of Medicine
City of Hope Medical Center
University of Florida
Northwell Health
H. Lee Moffitt Cancer Center and Research Institute
Vanderbilt University Medical Center
Ohio State University
Huntsman Cancer Institute
Columbia University
Information provided by (Responsible Party):
Paul G. Richardson, MD, Dana-Farber Cancer Institute

No Study Results Posted on for this Study
  Recruitment Status : Active, not recruiting
  Estimated Primary Completion Date : September 2018
  Estimated Study Completion Date : September 2018